Free Trial

Acorda Therapeutics (ACOR) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
416,900 shs
Average Volume
119,299 shs
Market Capitalization
P/E Ratio
Dividend Yield
Price Target
ACOR stock logo

About Acorda Therapeutics Stock (NASDAQ:ACOR)

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.

ACOR Stock News Headlines

Acorda Therapeutics Announces Delisting from Nasdaq
Acorda Therapeutics Inc.
Stocks to Watch: PVH, Canoo, Acorda Therapeutics
3 Biotech Stocks to Watch in March for Success
Acorda: No policy vs. TikTok use in PNP
See More Headlines
Receive ACOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$117.63 million
Book Value
($127.17) per share


Free Float
Market Cap
No Data

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Ron Cohen M.D. (Age 68)
    Founder, CEO, President & Director
    Comp: $984.15k
  • Mr. Michael A. Gesser M.B.A. (Age 61)
    Chief Financial Officer
    Comp: $459.15k
  • Mr. Kerry M. Clem (Age 54)
    Chief Commercial Officer
    Comp: $592.23k
  • Mr. Robert Morales (Age 56)
    Interim Principal Accounting Officer, Principal Financial Officer, VP of Finance & Controller
  • Ms. Felicia Vonella
    Vice President of Investor Relations
  • Mr. Neil S. Belloff Esq. (Age 64)
    General Counsel & Corporate Secretary
  • Ms. Tierney Saccavino
    Executive Vice President of Corporate Communications
  • Ms. Denise J. Duca
    Executive Vice President of Human Resources
  • Mr. Andrew Mayer J.D.
    Senior Vice President
  • Sofia Ali
    Senior VP of Operations & Strategic Planning

ACOR Stock Analysis - Frequently Asked Questions

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics, Inc. (NASDAQ:ACOR) issued its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($28.60) earnings per share for the quarter, topping analysts' consensus estimates of ($31.20) by $2.60. The biopharmaceutical company earned $31.46 million during the quarter, compared to analysts' expectations of $30.57 million. Acorda Therapeutics had a negative net margin of 214.95% and a negative trailing twelve-month return on equity of 2,206.93%.

When did Acorda Therapeutics' stock split?

Acorda Therapeutics's stock reverse split on Monday, June 5th 2023. The 1-20 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Ron Cohen's approval rating as Acorda Therapeutics' CEO?

39 employees have rated Acorda Therapeutics Chief Executive Officer Ron Cohen on Ron Cohen has an approval rating of 55% among the company's employees. This puts Ron Cohen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Acorda Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), InterDigital (IDCC), Nektar Therapeutics (NKTR), Rigel Pharmaceuticals (RIGL), Novan (NOVN), SCYNEXIS (SCYX), Acasti Pharma (ACST) and Applied Materials (AMAT).

Who are Acorda Therapeutics' major shareholders?

Acorda Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends

This page (NASDAQ:ACOR) was last updated on 5/29/2024 by Staff

From Our Partners